Global Acute Lymphocytic or Lymphoblastic Leukaemia (ALL) Therapeutics Market is Estimated to Value Over USD 3.4 Billion by 2026 End

  • 13 Sep 2019

Global Acute Lymphocytic or Lymphoblastic Leukaemia (ALL) Therapeutics Market is estimated to value over USD 3.4 billion by 2026 end and register a CAGR of over 5% during the forecast period 2019 to 2026.

Increase in initiatives undertaken by private and public organizations and growing incidence of Acute Lymphoblastic Leukaemia (ALL) are some of the key factors expected to drive acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics market growth.

Advancements in technology made for detecting affected cells are considered as one of the drivers for Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market growth. For example, Novartis AG’s Chimeric Antigen Receptor T-cell therapy is an innovative therapy. 

Many nongovernment and government organizations, such as the National Institutes of Health, the National Cancer Institute (NCI), the American Cancer Society and the Foundation for the, have arranged diagnostic campaigns and undertaken initiatives for detection of ALL.

Moreover, the “Therapeutically Applicable Research to Generate Effective Treatments (TARGET)” initiative with collaboration with many research groups and launched multiple programs across different countries such as the University of New Mexico and St. Jude Children’s Research Hospital etc., to provide facilities to patients for better treatment and early diagnosis of Leukaemia.


ALL treatment consists of different therapies such as targeted therapy, chemotherapy, stem cell transplant and radiation therapy. Chemotherapy segment led the market in 2016 due to factors like its ability to prevent thriving & multiplication of cancerous cells and destroy Leukaemia cells that restrain the progress of the disease. All these factors are responsible for the increase in the rate of prescription of chemotherapy for the last decade, thus expanding the acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics market size. In chemotherapy, single or combination drugs are used for treating ALL. This therapy includes antimetabolites, alkylating agents, cytotoxic agents, and other plant derivatives. Additionally, stem cell transplant can be used together with chemotherapy, which helps healthcare practitioners instigate chemotherapy infusions at high doses for effective treatment.


ALL is categorised into three types- precursor B-ALL, Philadelphia (Ph) chromosome and T-cell ALL. The Philadelphia (Ph) chromosome is further bifurcated into Ph-negative ALL and Ph-positive ALL. The chances of acquiring this disease increase with age. The drugs used for the treatment of ALL are usually tyrosine kinase inhibitors like imatinib (Glivec), dasatinib (Sprycel), , and nilotinib (Tasigna). The aforementioned drugs have many indications with acute lymphoblastic leukaemia as one of them. 


Key market players include Erytech Pharma, Spectrum Pharmaceuticals Inc., Bristol-Myers Squibb Company, Genzyme Corp. (Sanofi), Pfizer Inc., Sigma-tau spa, Novartis AG, Celegene Corp., Juno Therapeutics Inc.


Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Segmentation:

By Product

  • Chemotherapy
    • Hyper-CVAD
    • CALGB 8811 Regimen
    • Linker Regimen
    • Nucleoside Metabolic Inhibitors
    • Oncaspar
  • Targeted Therapy
  • Radiation Therapy
  • Stem Cell Transplantation

 By Type

  • Philadelphia Chromosome
    • Positive Ph (Ph+)
    • Negative Ph (Ph-)
  • Precursor B-Cell ALL
  • T-Cell ALL

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa


FutureWise Key Takeaways:

• Growth prospects

• SWOT analysis 

• Key trends 

• Key data-points affecting market growth 


Objectives of the Study:

  • To provide with an exhaustive analysis on the global acute lymphocytic/lymphoblastic Leukaemia (ALL) therapeutics market by product, by type and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market 
  • To predict the market size, in key regions (along with countries)— North America, Asia Pacific, Europe, Latin America and Middle East & Africa
  • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • Profiling of companies to evaluate their market shares, strategies, financials and core competencies


Get unlimited analyst support and customise this study further to your requirements, contact